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47 patients were considered 'suitable', 23 'cautionary' and 5 
'unsuitable'. According to GEC-ESTRO, 60 were 'low risk', 7 
'intermediate risk' and 8 'high risk'. 69 patients were defined 
as 'acceptable' and 6 as 'not acceptable' following ABS 
recommendations. 46 of ABS 'acceptable' patients were also 
either 'suitable' or 'low risk' according to ASTRO and GEC-
ESTRO, meaning an accordance rate between guidelines on 
who to definitely treat with APBI of 67%. 6% (n=4) of patients 
with clear indication not to treat by ASTRO and/or GEC-
ESTRO fitted the 'acceptable' group criteria by ABS. No loco-
regional relapses were documented, 1 patient developed 
distant metastasis. 
Conclusions: This study shows a lack of agreement between 
the current guidelines and supports the existing evidence 
that APBI with multicatheter brachytherapy is an effective 
adjuvant treatment modality. 
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Purpose/Objective: To evaluate the role of 3T 
multiparametric MRI (3TmMRI) without endo-rectal coil (ERC) 
in the detection of radiographic local recurrences (rLR) in a 
contemporary cohort of patients with prostate cancer treated 
at our hospital and who presented a biochemical recurrence 
after PR with low PSA levels and to identify clinical 
parameters associated with the findings of the 3TmMRI.  
Materials and Methods: Between 2009 and 2013, 57 patients 
with biochemical recurrence after RP of a PC and considered 
for salvage radiation therapy (SRT) were included. 3TmMRI 
with T2-weighted imaging (T2WI), diffusion weighted imaging 
(DWI) and dynamic contrast-enhanced images (DCE) without 
ERC was carried out in all the patients prior to treatment. 
Given that there are no validated criteria, a points system 
was established to define the findings of the 3TmMRI, 0 being 
(normal; no abnormality was observed in the MRI sequences: 
T2WI, DWI or DCE), 1 being (doubtful; an abnormality was 
detected in one of the MRI sequences, with no correlation in 
the rest of the sequences) and 2 being (abnormal; 
abnormality detected in all or in two of the sequences). The 
local relapse was defined as 2. To analyze the relationship 
between rLR in 3TmMRI and the clinical variables, a logistic 
regression analysis was carried out. 
Results: In 14/57 patients (24.56%) a rLR through 3TmMRI 
was detected. Median pre-SRT PSA was 0.40 ng/ml 
(interquartile range, 0.30-2.05 ng/ml). The location of the 
recurrence was perianastomotic in 8/14 patients (57.14%) 
and retrovesical in 6/14 patients (42.86%). The median size 
of the local recurrence was 15.2 mm (range, 8.0-46.0 mm). 
The median apparent diffusion coefficient (ADC) value on 
DWI was 0.90 mm2/s (range, 0.35-1.58 mm2/s) and 6/14 
patients (42.85%) presented type 3 pathological captation 
curves and 3/14 patients (21.42%) presented type 2 
enhancement curves in the DCE images. Normal prostate 
tissue remains were identified in 9/57 patients (15.78%). 
Pelvic nodal recurrence was evidenced in 4/57 patients 
(7.01%) and pelvic bone metastasis were found in 4/57 
patients (7.01%). 12.90% (4/31) rLR was observed in patients 
with PSA ≤0.5 ng/ml, vs 38.46% (10/26) for PSA>0.5 ng/ml. 
The incidence of rLR according to PSA doubling time (PSADT) 
was 15.% (6/40) for PSADT≤14 months, vs 54.54% (6/11) for 
PSADT>14 months. The probability of rLR was significantly 
higher in patients with PSA levels >0.5 ng/ml (adjusted odds 
ratio (OR): 6.25; 95% confidence interval (CI): 1.27-
30.79;p=0.02), or PSA doubling time (PSADT)>14 months 
(adjusted OR: 7.12; 95% CI:1.40-36.25; p=0.01). 
Conclusions: This is the first study to find a significant 
relationship between the PSADT and the rLR through MRI. 
Patients that benefit most from conducting a 3TmMRI were 
those with PSADT>14 months or with pre-SRT PSA >0.5 ng/ml. 
Its routine use could have significant clinical implications in 
SRT. 
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Purpose/Objective: Recent EORTC studies report an increase 
in survival in breast cancer patients treated with RT when 
the internal mammary node (IMN) is included. The 
aforementioned studies were based on conventional 3D 
irradiation with photons in breast and supraclavicular and 
axillary nodes and a direct electron field in the IMN. To our 
knowledge, the safety of including IMN in IMRT has not been 
studied to date. The objective of the study was to 
retrospectively evaluate the dosimetric impact on the usual 
organs at risk (OAR) in the irradiation of the left breast/chest 
wall (heart, lungs, and contralateral breast) treated with 
IMRT. 
Materials and Methods: We selected all breast patients (n = 
30) treated with IMRT (left breast, left chest wall, 
with/without nodes and with/without boost) in 2014. CT 
planning was performed in all patients with a Philips Big Bore 
CT. We defined the volumes to irradiate and the OAR. We 
performed a new IMRT planning to compare with the previous 
technique. We used our standard distribution of fields in each 
case. Treatment planning and volume definition were defined 
using the Eclipse V8.9 planning system from Varian. After 
optimizing dosimetry to obtain the best coverage and 
homogeneous distribution of PTVs, we compared the dose 
received in OAR for each of the 2 plans, considering the 
constraints of our service (mainly based in QUANTEC), which 
are: 
-Heart: V30<30%; V25<15; Dmean<10Gy 
-Lung: V5<60%; V20<30% 
-Ipsilateral Lung: V20<30% 
-Contralateral Lung: V5<40% 
-Contralateral Breast: V5<2% (This is an orientation constraint 
because heart and lung area priority constraint). 
We recorded the values of these indexes for IMRT with and 
without IMN. 
Results:  
Table 1 shows the mean values recorded for IMRT with and 
without IMN, and the differences between the two plans. We 
found a slight increase in dose in OAR when IMN was 
included, but this increase did not exceed the limits 
established in our service. 
 
 
 
 
Conclusions: IMN irradiation of the left breast can be safely 
performed with the new treatment techniques (IMRT) 
because it does not significantly increase the dose received 
by the OAR. 
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